

A - ORIGINAL ARTICLES IN PEER REVIEWED JOURNALS

(Alphabetisch nach Erstautor sortiert)

Acaster S, Swinburn P, Wang C, Stemper B, Beckmann K, Knappertz V, Pohl C, Sandbrink R, Gondek K, Edan G, **Kappos L**, Freedman M, Hartung HP, Arnason B, Comi G, Filippi M, Jeffery D, O'Connor P, Cook S, Lloyd A.

Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. *Mult Scler.* 2011;17(12):1504-13. IF: 4.230

Ahlhelm F, Lieb J, Ulmer S, **Sprenger T**, Stippich C, Kelm J. Entzündliche Erkrankungen der Wirbelsäule und des Myelons. *Radiologe* 2011;51(9):763-71. IF: 0.523

Altinbas A, van Zandvoort MJ, van den Berg E, Jongen LM, Algra A, Moll FL, Nederkoorn PJ, Mali WP, **Bonati LH**, Brown MM, Kappelle LJ, van der Worp HB. Cognition after carotid endarterectomy or stenting: a randomized comparison. *Neurology.* 2011 Sep 13;77(11):1084-90. IF: 8.017

Amann M, Dössegger LS, Penner IK, Hirsch JG, Raselli C, Calabrese P, Weier K, Radü EW, Kappos L, Gass A. Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing-remitting multiple sclerosis patients. *Hum Brain Mapp.* 2011 Oct;32(10):1704-19. IF: 5.107

Amort M, Fluri F, Schäfer J, Weisskopf F, Katan M, Burow A, Bucher HC, Bonati LH, Lyrer PA, Engelter ST. Transient ischemic attack versus transient ischemic attack mimics: frequency, clinical characteristics and outcome. *Cerebrovasc Dis.* 2011;32(1):57-64. IF: 2.987

Bassetti CL, Bornatico F, **Fuhr P**, Schwander J, Kallweit U, Mathis J. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. *Swiss Med Wkly.* 2011 Nov 21;141 IF: 1.823

Bendfeldt K, Hofstetter L, Kuster P, Traud S, Mueller-Lenke N, Naegelin Y, Kappos L, Gass A, Nichols TE, Barkhof F, Vrenken H, Roosendaal SD, Geurts JJ, Radue EW, Borgwardt SJ. Longitudinal gray matter changes in multiple sclerosis-Differential scanner and overall disease-related effects. *Hum Brain Mapp.* 2011 Apr 29. [Epub ahead of print] IF: 5.107

Birkenmaier A, Ries J, **Kuhle J**, Bürki N, Lapaire O, Hösli I. Placental α -microglobulin-1 to detect uncertain rupture of membranes and cost analysis in an European cohort of pregnancies. *Arch Gynecol Obstet*, Epub ahead of print, 2011 IF: 1.072

Bonati LH, Fraedrich G; Carotid Stenting Trialists' Collaboration. Age modifies the relative risk of stenting versus endarterectomy for symptomatic carotid stenosis - a pooled analysis of EVA-3S, SPACE and ICSS. *Eur J Vasc Endovasc Surg.* 2011 Feb;41(2):153-8. IF: 2.872

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoue A, Fratacci MD; PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial *Lancet.* 2011 Jun 11;377(9782):2013-22.. Erratum in: *Lancet.* 2011 Jul 30;378(9789):402 IF: 33.63 (**P. Lyrer, Investigator**)

Christine Buerge, Gregor Steiger, Stefan Kneifel, Stephan Wetzel, M. Axel Wollmer, Alphonse Probst, **Thomas P. Baumann**. Lobar Dementia due to Extreme Widening of Virchow-Robin Spaces in One Hemisphere. *Case Rep Neurol.* 2011 May-Aug; 3(2): 136–140. Kein IF

Bush WS, McCauley JL, Dejager PL, Dudek SM, Hafler DA, Gibson RA, Matthews PM, **Kappos L**, **Naegelin Y**, Polman CH, Hauser SL, Oksenberg J, Haines JL, Ritchie MD. A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. *Genes Immun.* 2011;12(5):335-40. IF: 4.367

Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggreffe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; PERFORM Study Investigators. PALLAS Investigators
Dronedarone in high-risk permanent atrial fibrillation
N Engl J Med. 2011 Dec 15;365(24):2268-76.
IF: 53.486 (**P. Lyrer, Investigator**)

Debette S, Metso TM, Pezzini A, Abboud S, Metso AJ, Leys D, Bersano A, Louillet F, Caso V, Lamy C, Medeiros E, Samson Y, Grond-Ginsbach C, **Engelter ST**, Thijs V, Beretta S, Bejot Y, Sessa M, Muiesan ML, Amouyel P, Castellano M, Arveiler D, Tattisumak T, Dallongeville J, for the CADISP-Group. Association of vascular risk factors with cervical artery dissection and ischemic stroke in young adults. *Circulation* 2011 Apr 12;123(14):1537-1544. IF: 14.432

Debette S, Grond-Ginsbach C, Bodenant M, Kloss M, **Engelter ST**, Metso T, Pezzini A, Brandt T, Caso V, Touzé E, Metso A, Canaple S, Abboud S, Giacalone G, **Lyrer P**, Del Zotto E, Giroud M, Samson Y, Dallongeville J, Tattisumak T, Leys D, Martin JJ; For the Cervical Artery Dissection Ischemic Stroke Patients (CADISP) Group
Differential features of carotid and vertebral artery dissections: The CADISP Study *Neurology.* 2011;77:1174-1181.
IF: 8.017

Di Fulvio S, Azakir BA, Therrien C, **Sinnreich M**, Dysferlin Interacts with Histone Deacetylase 6 and Increases alpha-Tubulin Acetylation. *PLoS One.* 2011;6(12):e28563. IF: 4.411

Doppler K, **Peyer A-K**, **Gobbi C**, **Fuhr P**, Arnold A, **Kappos L**, **Steck A**, Tolnay M, Frank S, **Renaud S**. Die Bestimmung der intraepidermalen Nervenfaserdichte in der Hautbiopsie - eine valide Methode zur Diagnostik von isolierten Small Fiber Neuropathien Erste Erfahrungen an der neurologischen Universitätsklinik Basel. *Schweizer Archiv für Neurologie und Psychiatrie* 2011; 162(1): 27-30 Kein IF

Duering M, Zieren N, Hervé D, Jouvent E, Reyes S, **Peters N**, Pachai C, Opherck C, Chabriat H, Dichgans M. Strategic role of frontal white matter tracts in vascular cognitive impairment: a voxel-based lesion-symptom mapping study in CADASIL. *Brain.* 2011 Aug;134(Pt 8): 2366-75. IF: 9.232

Duering M, Karpinska A, Rosner S, Hopfner F, Zechmeister M, **Peters N**, Kremmer E, Haffner C, Giese A, Dichgans M, Opherck C. Co-aggregate formation of CADASIL-mutant NOTCH3: a single-particle analysis. *Hum Mol Genet.* 2011 Aug 15;20(16):3256-65. IF: 8.058

Engelter ST, Amort M, Jax F, Weisskopf F, Katan M, Burow A, Bonati LH, Hatz F, Wetzel SG, Fluri F, Lyrer PA. Optimizing the risk estimation after a transient ischaemic attack - the ABCDE plus sign in circle score. *Eur J Neurol* 2011; 1468-1331. IF: 3.765

Engelter ST, Soenne L, Ringleb P, Sarikaya H, Bordet R, Berrouschot J, Odier C, Arnold M, Ford GA, Pezzini A, Zini A, Rantanen K, Rocco A, Bonati LH, Kellert L, Strbian D, Stoll A, Meier N, Michel P, Baumgartner RW, Leys D, Tatlisumak T, Lyrer PA. IV thrombolysis and statins. *Neurology*. 2011 Aug 30;77(9):888-95. IF: 8.017

Fanchamps MH, **Gensicke H, Kuhle J, Kappos L, Allum JH, Yaldizli O.** Screening for balance disorders in mildly affected multiple sclerosis patients. *J Neurol*. 2011 Dec 21. [Epub ahead of print] IF: 3.853

Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, **Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V.** Interferon β -1b and glatiramer acetate effects on permanent black hole evolution. *Neurology*. 2011;76(14):1222-8. IF: 8.017

Fischmann A, Gloor M, Fasler S, Haas T, Rodoni Wetzel R, Bieri O, Wetzel S, Heinemann K, Scheffler K, **Fischer D.** Muscular involvement assessed by MRI correlates to motor function measurement values in oculopharyngeal muscular dystrophy. *J Neurol*. 2011 Jul;258(7):1333-40 IF 3.853

Fluri F, Jax F, Amort M, Wetzel SG, Katan M, Lyrer PA, Hatz F, Engelter ST. Significance of microbleeds in patients with transient ischemic attacks. *Eur J Neurol* 2011 IF: 3.765

Fluri F, Hatz F, Voss B, Lyrer PA, Engelter ST. Etiology of late cerebrovascular events after carotid endarterectomy. *Eur J Neurol*. 2011, Feb;18(2):343-6. IF: 3.765

Freedman M, Metzger C, **Kappos L, Polman C, Edan G, Hartung HP, Miller D, Montalban X, Yarden J, Spector L, Fire E, Dotan N, Schwenke S, Lanius V, Sandbrink R, Pohl C.** Predictive nature of IgM anti- α -glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. *Mult Scler*. 2011 Dec 21. [Epub ahead of print]. IF: 4.230

Geurts JJ, Roosendaal SD, Calabrese M, Ciccarelli O, Agosta F, Chard DT, Gass A, Huerga E, Moraal B, Pareto D, Rocca MA, Wattjes MP, Yousry TA, Uitdehaag BM, Barkhof F; **MAGNIMS Study Group.** Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. *Neurology*. 2011;76(5):418-24. IF: 8.017 (**Kappos L, Member of study group / Steering committee**)

Gloor M, Fasler S, Fischmann A, Haas T, Bieri, Heinemann K, Scheffler K, **Fischer D.** Quantification of fat infiltration in oculopharyngeal muscular dystrophy: comparison of three MRI methods. *J Magn Reson Imaging*. 2011 Jan;33(1):203-10, IF 2.749

Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, **Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C.** Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. *Mult Scler*. 2011 Sep 30. [Epub ahead of print] IF: 4.230

M. Goodkind, **M. Sollberger**, A. Gyurak, H. J. Rosen, K. P. Rankin, B. Miller, R. Levenson. Tracking emotional valence: The role of the orbitofrontal cortex. *Human Brain Mapping*. 2011 Mar 21 IF 5.107

Hartung HP, Freedmann MS, Polman CH, Edan G, **Kappos L, Miller DH, Montalbán X,**

- Barkhof F, Petkau J, White R, Sahajpal V, Knappertz V, Beckmann K, Lanius V, Sandbrink R, Pohl C; for the BENEFIT Study Group. Interferon {beta}-1b-neutralizing antibodies 5 years after clinically isolated syndrome. *Neurology*. 2011;77(9):835-843. IF: 8.017
- Held K, Eiglmeier I, Himmelein S, Sinicina I, Brandt T, Theil D, Dornmair K, **Derfuss T**: Clonal expansions of CD8+ T-cells in latently HSV-1 infected human trigeminal ganglia. *J Neurovirol* 2011 IF: 2.243
- Held K, Junker A, Dornmair K, Meinl E, Sinicina I, Brandt T, Theil D, **Derfuss T**: Expression of HSV-1 encoded miRNAs in human trigeminal ganglia and their relation to local T-cell infiltrates. *J. Virology* 2011; 85(19):9680-5. IF: 5.189
- Hilbert P**, Frank S, Raheem, Suominen, Penttilä, Udd B, **Fischer D**. Normal muscle MRI does not preclude increased connective tissue in muscle of recessive myotonia congenita. *Acta Neurol Scand*. 2011 Aug;124(2):146-7 IF 2.153
- Kappos L**, Li D, Calabresi P A, O'Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser S L. Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: Results of a Phase II Randomized Placebo-Controlled Multicenter Trial. *Lancet*. 2011;378(9805):1779-87. IF: 33.633
- Kappos L**, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, Dawson K, O'Neill GN. Effect of BG-12 on contrast-enhancing lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study. *Mult Scler*. 2011 Aug 30. [Epub ahead of print] IF: 4.230
- Katan M**, Nigro N, **Fluri F**, Schuetz P, Morgenthaler NG, Jax F, Meckel S, Gass A, Bingisser R, **Steck A**, **Kappos L**, **Engelter S**, Müller B, Christ-Crain M. Stress hormones predict cerebrovascular re-events after transient ischemic attacks. *Neurology*. 2011 Feb 8;76(6):563-6. IF: 8.017
- Khatri B, Barkhof F, Comi G, Hartung HP, **Kappos L**, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; on behalf of the TRANSFORMS Study Group. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. *Lancet Neurol*. 2011;10(6):520-529. IF: 21.659
- Kuhle J**, Gosert R, Bühler R, **Derfuss T**, Sutter R, **Yaldizli O**, Radue EW, Ryschkewitsch C, Major EO, **Kappos L**, Frank S, Hirsch HH: Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. *Neurology*. 2011; 77(23):2010-6. IF: 8.017
- Kuhle J**, Leppert D, Petzold A, Regeniter A, Schindler C, **Mehling M**, Anthony DC, **Kappos L**, **Lindberg R**. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. *Neurology*, 76 (14), 1206-1213, 2011 IF: 8.017
- Leppa V, Surakka I, Tienari PJ, Elovaara I, Compston A, Sawcer S, Robertson N, De Jager PL, Aubin C, Hafler DA, Oturai AB, Bach Søndergaard H, Sellebjerg F, Soelberg Sørensen P, Hemmer B, Cepok S, Winkelmann J, Wichmann HE, Comabella M, Bustamante MF, Montalban X, Olsson T, Kockum I, Hillert J, Alfredsson L, Goris A, Dubois B, Mero IL, Smestad C, Celius EG, Harbo HF, D'Alfonso S, Bergamaschi L, Leone M, Ristori G, **Kappos L**, Hauser SL, Cournu I, Fontaine B, Boonen S, Polman C, Palotie A, Peltonen L, Saarela J.

The genetic association of variants in CD6, TNFRSF1A and IRF8 to multiple sclerosis: a multicenter case-control study. *PLoS One*. 2011;6(4):e18813 IF: 4.411

MacManus DG, Miller DH, **Kappos L**, Gold R, Havrdova E, Limmroth V, Polman CH, Schmierer K, Yousry TA, Eraksoy M, Meluzinova E, Dufek M, Yang M, O'Neill GN, Dawson K
BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. *J Neurol*. 2011;258(3):449-56. IF: 3.853

Mehling M, Hilbert P, Fritz S, Durovic B, Eichin D, Gasser O, **Kuhle J**, Klimkait T, **Lindberg R, Kappos L**, Hess C. Antigen-specific adaptive immune responses in fingolimod-treated MS patients. *Ann Neurol*, 69 (2), 408-413, 2011 IF: 10.746

Metso AJ, Metso TM, Debette S, Dallongeville J, **Lyrer PA**, Pezzini A, Lichy C, Kloss M, Brandt T, Touzé E, Southerland AM, Worrall BB, Abboud S, Del Zotto E, Leys D, **Engelter S**, Grond-Ginsbach C, Tatlisumak T; for the CADISP group
Gender and cervical artery dissection
Eur J Neurol. 2011; [Epub ahead of print] IF: 3.765

Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, **Kuhle J**, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W.
Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.
Acta Neuropathol, epub, 2011 IF: 7.695

Montalban X, Comi G, O'Connor P, Gold S, de Vera A, Eckert B, **Kappos L**.
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. *Mult Scler*. 2011;17(11):1341-50. IF: 4.230

Neidert S, **Katan M**, Schuetz P, **Fluri F**, Ernst A, Bingisser R, **Kappos L, Engelter ST, Steck A**, Müller B, Christ-Crain M Anterior pituitary axis hormones and outcome in acute ischaemic stroke. *J Intern Med*. 2011 Apr;269(4):420-32. IF: 5.935

Nigro N, Müller B, Morgenthaler NG, **Fluri F**, Schütz P, Neidert S, Stolz D, Bingisser R, Tamm M, Christ-Crain M, **Katan M**. The use of copeptin, the stable peptide of the vasopressin precursor, in the differential diagnosis of sodium imbalance in patients with acute diseases. *Swiss Med Wkly*. 2011 Oct 11;141:w13270. IF: 1.823

O'Connor PW, Goodman A, **Kappos L**, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
Neurology. 2011;76(22):1858-65. IF: 8.017

O'Connor P, Wolinsky J, Confavreux C, Comi G, **Kappos L**, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedmann MS, TEMSO TRIAL GROUP
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
N Engl J Med. 2011;365(14):1293-303. IF: 53.486

Osthoff M, **Katan M, Fluri F**, Schuetz P, Bingisser R, **Kappos L, Steck AJ, Engelter ST**, Mueller B, Christ-Crain M, Trendelenburg M. Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients. *PLoS One*. 2011;6(6):e21338. IF: 4.411

Papić L, **Fischer D**, Trojanovski S, Höftberger R, Auer-Grumbach et al. SNP-whole genome homozygosity mapping: a quick and powerful tool to achieve an accurate diagnosis in LGMD2 patients. *Eur J Med Genet*. 2011 May-Jun;54(3):214-9. IF 2.335

Peters N, Holtmannspötter M, Büttner U. Valsalva-maneuver induced recurrent transient bilateral visual loss. *Clin Neurol Neurosurg*. 2011;113(2):150-2. IF: 1.636

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, **Kappos L**, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. *Ann Neurol*. 2011;69(2):292-302. IF: 10.746

Pröbstel AK, Dornmair K, Bittner R, Sperl P, Jenne D, Magalhaes S, Villalobos A, Breithaupt C, Weissert R, Jacob U, Krumbholz M, Kuempfel T, Blaschek A, Stark W, Gärtner J, Pohl D, Rostasy K, Weber F, Forne I, Khademi M, Olsson T, Brilot F, Tantsis E, Dale RC, Wekerle H, Hohlfeld R, Banwell B, Bar-Or A, Meinl E, **Derfuss T**: Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. *Neurology* 2011; 77(6):580-8. IF: 8.017

Puetz V, Khomenko A, Hill MD, Dzialowski I, Michel P, Weimar C, Wijman CA, Mattle HP, **Engelter ST**, Muir KW, Pfefferkorn T, Tanne D, Szabo K, Kappelle LJ, Algra A, von Kummer R, Demchuk AM, Schonewille WJ; on behalf of the Basilar Artery International Cooperation Study (BASICS) Group. Extent of Hypoattenuation on CT Angiography Source Images in Basilar Artery Occlusion: Prognostic Value in the Basilar Artery International Cooperation Study. *Stroke* Dec;42(12):3454-3459. IF: 5.756

Riedl V, Valet M, Woeller A, Sorg C, Vogel D, **Sprenger T**, Boecker H, Wohlschlaeger AM, Toelle TR. Repeated pain induces adaptations of intrinsic brain activity to reflect past and predict future pain. *Neuroimage* 2011;57(1):206-13. IF: 5,937

Rigotti D, Gass A, **Achtnichts L**, Inglese M, Babb J, **Naegelin Y**, Hirsch J, **Amann M**, **Kappos L**, Gonen O. Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment. *Mult Scler*. 2011 Oct 21. [Epub ahead of print] IF: 4.230

Roosendaal SD, Bendfeldt K, Vrenken H, Polman CH, Borgwardt S, Radue EW, **Kappos L**, Pelletier D, Hauser SL, Matthews PM, Barkhof F, Geurts JJ. Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. *Mult Scler*. 2011; 17(9):1098-106. IF: 4.230

Rudick R, **Kappos L**, Kinkel R, Clanet M, Philips J, Herndorn R, Sanrock A, Munschauer F 3rd. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients. *Mult Scler*. 2011;17(3):353-60. IF: 4.230

Rudin D, Grize L, Schindler C, Marsch S, **Rüegg S**, **Sutter R**. High prevalence of nonconvulsive status epilepticus in an ICU of a tertiary care center: a three—year observational cohort study. *Epilepsy Res* 2011; 96: 140-50. IF: 2.302

Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, Whiteley W, Perry D, Soosay V, Buchanan D, Venables G, Czlonkowska A, Kobayashi A, Berge E, Slot KB, Murray V, Peeters A, Hankey GJ, Matz K, Brainin M, Ricci S, Cantisani TA, Gubitz G, Phillips SJ, Arauz A, Correia M, **Lyrer P**, Kane I, Lundstrom E, Ist-3 Collaborative Group OB
Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited
Trials. 2011 Nov 30;12(1):252.
IF: 2.080

Sarikaya H, Arnold M, **Engelter ST**, **Lyrer PA**, Mattle HP, Georgiadis D, **Bonati LH**, **Fluri F**, Fischer U, Findling O, Ballinari P, Baumgartner RW. Outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke. *Stroke*.

2011 Sep;42(9):2498-502. IF: 5.756

Sarikaya H, Arnold M, **Engelter ST, Lyrer PA**, Michel P, Odier C, Weder B, Tettenborn B, Mueller F, Sekoranja L, Sztajzel R, Ballinari P, Mattle HP, Baumgartner RW Intravenous Thrombolysis in Nonagenarians With Ischemic Stroke. *Stroke*. 2011;42(7):1967-70 IF: 5.756

Sarikaya H, Arnold M, **Engelter ST, Lyrer PA**, Mattle HP, Michel P, Odier C, Weder B, Siebel P, Mueller F, Ballinari P, Georgiadis D, Baumgartner RW Outcome of Intravenous Thrombolysis in Stroke Patients Weighing over 100 kg *Cerebrovasc Dis*. 2011 Aug 4;32(3):201-206 IF: 2.987

Schlaeger R, D'Souza M, Schindler C, Grize L, **Kappos L, Fuhr P**. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. *Clin Neurophysiol*. 2011; 123(2):406-10 IF: 2.786

Schlaeger R, D'Souza M, Schindler C, Grize L, Dellas S, Radue E, **Kappos L, Fuhr P**. Prediction of long-term disability in multiple sclerosis. *Mult Scler*. 2011; 18(1):31-8 IF: 4.230

Schlede N, Zimmermann R, Ehrensperger MM, Gschwandtner U, **Hardmeier M, Hatz F**, Monsch AU, **Naegelin Y, Fuhr P**. Clinical EEG in cognitively impaired patients with Parkinson's Disease. *J Neurol Sci*. 2011 Jun 24. [Epub ahead of print] IF: 2.167

Schubert T, Santini F, Stalder AF, Bock J, Meckel S, **Bonati L**, Markl M, Wetzel S. Dampening of blood-flow pulsatility along the carotid siphon: does form follow function? *AJNR Am J Neuroradiol*. 2011 Jun-Jul;32(6):1107-12. IF: 3.464

Schuster C, Maunz G, Lutz K, Kischka U, **Sturzenegger R**, Ettl T. Dexamphetamine improves upper extremity outcome during rehabilitation after stroke: a pilot randomized controlled trial. *Neurorehabil Neural Repair*. 2011 Oct;25(8):749-55. IF: 3.772

Seifert CL, Valet M, Pfaffenrath V, Boecker H, R  ther KV, T  lle TR, **Sprenger T**. Neurometabolic correlates of depression and disability in patients with severe episodic pain. *J Neurol* 2011;258(1):123-31. IF: 3.853

Seifert CL, **Sprenger T**, Muecke T, Foerschler A, Poppert H, Hemmer B, Sellner J. Systemic thrombolysis in ischemic stroke after recent oral surgery and management of oral cavity bleeding. *Annals of Emergency Med* 2011;57(5):517-9. IF: 4,142

Seifert CL, Wegner C, **Sprenger T**, Weber MS, Br  ck W, Hemmer B, Sellner J. Favorable response to plasma exchange in tumefactive CNS demyelination. *Mult Scler* 2011 [Epub ahead of print]. IF: 4.230

M. Sollberger, C. M. Stanley, R. Ketelle, V. Beckman, M. Growdon, J. Jang, J. Neuhaus, J. H. Kramer, B. L. Miller, K. P. Rankin. Neuropsychological correlates of dominance, warmth, and extraversion in neurodegenerative disease. *Cortex* 2011 Mar 10 IF 7.251

Sombekke MH, Jafari N, **Bendfeldt K, Mueller-Lenke N**, Radue EW, **Naegelin Y, Kappos L**, Matthews PM, Polman CH, Barkhof F, Hintzen R, Geurts JJ. No influence of KIF1B on neurodegenerative markers in multiple sclerosis. *Neurology*. 2011;76(21):1843-5. IF: 8.017

Steck A, Kinter J, **Renaud S**. DNA microarray analysis in nerve biopsies of patients with vasculitic neuropathy. *Rev Neurol (Paris)*. 2011 Dec;167(12):927-9. Epub 2011 Nov 17. French. IF: 0.528

Steck AJ, Kinter J, **Renaud S**. Differential gene expression in nerve biopsies of inflammatory neuropathies. *J Peripher Nerv Syst*. 2011 Jun;16 Suppl 1:30-3. IF: 3.032

Steinacker P, Fang L, **Kuhle J**, Petzold A, Tumani H, Ludolph AC, Otto M, Brettschneider J. Soluble beta-amyloid precursor protein is related to disease progression in amyotrophic lateral sclerosis. *PLoS One*, 6(8), Epub ahead of print, 2011 IF: 4.411

Sutter R, Fuhr P, Grize L, Marsch S, **Rüegg S**. Continuous video-EEG monitoring increases detection rate of nonconvulsive status epilepticus in the ICU. *Epilepsia*. 2011 Mar;52(3):453-7. IF: 3.955

Sutter R, Tschudin-Sutter S, Grize L, Widmer AF, Marsch S, **Rüegg S**. Acute phase proteins and white blood cell levels for prediction of infectious complications in status epilepticus. *Crit Care* 2011; 15: R246. IF: 4.60

Sutter R, Tschudin-Sutter S, Grize L, **Fuhr P**, Bonten M, Widmer AF, Marsch S, **Rüegg S**. Infectious complications in status epilepticus: Evidence from a five-year observational cohort study. *Epilepsia* 2011; 52 (Suppl 9): S1-3. IF: 3.955

Sutter R, Mengiardi B, Benz D, Heijnen I, **Kappos L**, **Winkler DT**. Facial nerve palsy and anti-Ku autoantibodies. *J Neurol*. 2011 Jul 18. [Epub ahead of print] IF: 3.853

Treves S, Vukcevic M, Jeannet PY, Levano S, Girard T, Urwyler A, **Fischer D**, Voit T, Jungbluth H, Lillis S, Muntoni F, Quinlivan R, Sarkozy A, Bushby K, Zorzato F. Excitation coupled Ca²⁺ entry is associated with nuclear translocation of NFAT and may lead to high circulating levels of IL-6 in CCD patients. *Hum Mol Genet*. 2011 Feb 1;20(3):589-600. Erratum in: *Hum Mol Genet*. 2011 May 15;20(10):2079. IF: 8.058

Uitdehaag B, Constantinescu C, Cornelisse P, Jeffery D, **Kappos L**, Li D, Sandberg-Wollheim M, Traboulsee A, Verdun E, Rivera V. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. *Ther Adv Neurol Disord*. 2011;4(1):3-14.

Ullrich N*, **Fischer D***, Kornblum C, Walter MC, Niggli E, Zorzato F, Treves S. Alterations of excitation-contraction coupling and excitation coupled Ca²⁺ entry in human myotubes carrying CAV3 mutations linked to rippling muscle disease. *Hum Mutat*. 2011 Mar;32(3):309-17 (*equally contributed) IF 5.956

Paola Valsasina, Maria A. Rocca, Martina Absinta, Maria Pia Sormani, Laura Mancini, Nicola De Stefano, Alex Rovira, **Achim Gass**, Christian Enzinger, Frederik Barkhof, Christiane Wegner, Paul M. Matthews and Massimo Filippi, A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. *European Journal of Neuroscience*, Vol. 33, pp. 1256–1263, 2011 IF: 3.658

Vermersch P, **Kappos L**, Gold R, Foley J, Olsson T, Cadavid D, Bozic C, Richman S. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. *Neurology*. 2011;76(20):1697-704. IF: 8.017

Viana M, Glastonbury, **Sprenger T**, Goadsby PJ. Trigeminal neuropathic pain in a patient with progressive facial hemiatrophy (parry-romberg syndrome). *Arch Neurol* 2011;68 (7): 938-943. IF: 7.108

Wachter M, **Katan M**, Muzzarelli S, Rohner A, Christ-Crain M, **Fluri F**, Bernheim AM. The role of routine echocardiography in unselected patients with cerebrovascular ischaemic events. *Eur J Neurol*. 2011 Jun;18(6):925-8. IF: 3.765

Wang JH, Pappas D, De Jager PL, Pelletier D, de Bakker PI, **Kappos L**, Polman CH; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Chibnik LB, Hafler DA, Matthews PM, Hauser SL, Baranzini SE, Oksenberg JR. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. *Genome Med.* 2011;3(1):3. IF: 1.662

Waschbisch A, Atiya M, Potapov S, Schwab S, Linker R, **Derfuss T**: Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. *Plos One* 2011; 6(9):e24604. IF: 4.411

Waschbisch A, Sandbrink R, Hartung HP, **Kappos L**, Schwab S, Pohl C, Wiendl H. Evaluation of soluble HLA-G as a biomarker for multiple sclerosis. *Neurology.* 2011;77(6):596-8. IF: 8.017

Weber M, Neuwirth C, Thierbach J, **Schweikert K**, Czaplinski A, Petersen J, Jung HH, Birve A, Marklund SL, Andersen PM. ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival. *J Neurol Neurosurg Psychiatry.* 2011 Jun 23. [Epub ahead of print] No abstract available. IF: 4.791

Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, **Kappos L**, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. *J Neurol.* 2011 Oct 19. [Epub ahead of print] IF: 3.853

Yaldizli O, Glasl S, Sturm D, **Papadopoulou A**, **Gass A**, Tettenborn B, Putzki N. Fatigue and progression of corpus callosum atrophy in multiple sclerosis. *J Neurol.* 2011 Dec;258(12):2199-205. IF: 3.853

Zweifel C, **Katan M**, Schuetz P, Ernst A, Mariani L, Müller B, Christ-Crain M. Growth hormone and outcome in patients with intracerebral hemorrhage: a pilot study. *Biomarkers.* 2011 Sep;16(6):511-6. IF: 2.090

Zinkstok SM, Vergouwen MD, **Engelter ST**, **Lyrer PA**, **Bonati LH**, Arnold M, Mattle HP, Fischer U, Sarikaya H, Baumgartner RW, Georgiadis D, Odier C, Michel P, Putaala J, Griebbe M, Wahlgren N, Ahmed N, van Geloven N, de Haan RJ, Nederkoorn PJ. Safety and functional outcome of thrombolysis in dissection-related ischemic stroke: a meta-analysis of individual patient data. *Stroke* 2011; Sep;42(9):2515-20. IF: 5.756

B - BUCHBEITRÄGE, EDITORIALS & REVIEWS 2011

(Alphabetisch nach Erstautor sortiert)

Barkhof F, Simon JH, Fazekas F, Rovaris M, **Kappos L**, de Stefano N, Polman CH, Petkau J, Radue EW, Sormani MP, Li DK, O'Connor P, Montalban X, Miller DH, Filippi M.
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. *Nat Rev Neurol*. 2011;8(1):13-21. IF: 6.511

Gensicke H, Leppert D, Yaldizli Ö, Nägelin Y, Lindberg R, Mehling M, Kappos L, Kuhle J.
Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis. *CNS Drugs*, 2011 IF: 4.497

Held K, **Derfuss T**: Control of HSV-1 latency in human Trigeminal Ganglia – current overview. *J Neurovirol* 2011_Dec;17(6):518-27 IF: 2.243

Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdová E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, O'Connor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radü EW, Sørensen PS, King J.
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurol*. 2011;10(8):745-58. IF: 21.659

Kappos L, Li D, Hauser SL, et al.
Ocrelizumab succeeds in phase 2 trial, broadening the ms treatment landscape. *Neurology Today* November 2011; p. 1, 15-17

Katan M, Elkind MS. Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke. *Expert Rev Neurother*. 2011 Feb;11(2):225-39

Kuhle J, Petzold A.
What makes a prognostic biomarker in CNS diseases: strategies for discovery? Part 1: acute and monophasic diseases. *Expert Opin Med Diagn*, 5(4), 333-346, 2011

Kuhle J, Petzold A.
What makes a prognostic biomarker in CNS diseases: strategies for discovery? Part 2: chronic progressive and relapsing diseases. *Expert Opin Med Diagn*, 5(5), 393-410, 2011

Lorscheider J, Derfuss T: MS-Therapie: aktueller Stand und Aussichten für die Zukunft. *Neurologie & Psychiatrie* 2011

Mehling M, Kappos L, Derfuss T, Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions. *Curr Neurol Neurosci Rep*. 2011 Oct;11(5):492-7 IF: 2.697

Mehling M, Johnson TA, Antel J, **Kappos L**, Bar-Or A, Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. *Neurology*. 2011 Feb 22;76(8 Suppl 3):S20-7. IF: 8.017

Quijano-Roy S, Carlier RY, **Fischer D**. Muscle imaging in congenital myopathies. *Semin Pediatr Neurol*. 2011 Dec;18(4):221-9. IF 1.862

Rüegg S. Editorial "Epilepsie und Hormone". *Epileptologie* 2011; 28: 1-66.

Rüegg S. Epilepsie und Schilddrüse. *Epileptologie* 2011; 28: 30-41.

Rüegg S. Seeck M, Meyer K, Krämer G. Einsatz von Antiepileptika-Generika in der Epilepsie-Therapie. *SAeZ* 2011; 92: 1909-11.

Sprenger T. Comment on: Zebenholzer K, Rudel E, Frantal S, Brannath W, Schmidt K, Woeber-Bingoel C, Woeber C. Migraine and weather: A prospective diary-based analysis. *Cephalalgia* 2011;31:391. *Journal Watch Neurology* 2011;13(5):38.

Sprenger T, Valet M, Tölle TR. Funktionelle Bildgebung bei Schmerz. In: Baron R, Koppert W, Strumpf M, Willweber-Strumpf A (Hrsg.), *Praktische Schmerztherapie*, Springer Verlag, 2. Auflage (*Erscheinungsdatum: Februar 2011*).

Sprenger T, Seifert, C, Goadsby P. Imaging Activation in the migraine state. In: Borsook D, Goadsby PJ, Hargreaves R (eds.). *The migraine brain*. Oxford University Press, NY, in press.

Teunissen CE, Tumani H, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, Furlan R, Hintzen RQ, Hughes SG, Jimenez CR, Johnson MH, Killestein J, Krasulova E, **Kuhle J**, Magnone MC, Petzold A, Rajda C, Rejdak K, Schmidt HK, van Pesch V, Waubant E, Wolf C, Deisenhammer F, Giovannoni G, Hemmer B. Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. *Mult Scler Int*, epub, 2011.

Vetter M, Tzankov A, Engert A, **Mehling M**, Herrmann R, Rochlitz C. Hodgkin's Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature. *Case Rep Oncol*. 2011 Feb 25;4(1):106-14.6

Vezzani A, **Rüegg S**. Co-Editors of Proceedings of the First Meeting on "Immunity and inflammation in Epilepsy: mechanistic insights and therapeutic perspectives", (Milan, September 16-18, 2010). *Epilepsia* 2011; 52 (Suppl 3): S1-53. IF: 3.955

Vezzani A, **Rüegg S**. The pivotal role of immunity and inflammatory processes in Epilepsy is increasingly recognized: introduction. *Epilepsia* 2011; 52 (Suppl 3): S1-3. IF: 3.955

Vezzani A, **Rüegg S**. General conclusions. *Epilepsia* 2011; 52 (Suppl 3): S1-3. IF: 3.955

Waschbisch A, **Derfuss T**: Placebo controlled trials in MS: are they still needed? *Future Neurology* 2011

Yaldizli Ö, Kappos L

Klinische Grundlagen der Multiplen Sklerose.

In: *Multiple Sklerose verstehen und behandeln* von Regula Steinlin Egli, Springer Verlag 2011: pp.2-9.

Yaldizli O, Kuhle J, Derfuss T, Sprenger T, Kappos L, Neurologist-in-training, *Schweizer Archiv für Neurologie und Psychiatrie* 2011;162(4):171–3

Zinkstok SM, Vergouwen MD, **Engelter ST, Lyrer PA, Bonati LH**, Arnold M, Mattle HP, Fischer U, Sarikaya H, Baumgartner RW, Georgiadis D, Odier C, Michel P, Putaala J, Griebbe M, Wahlgren N, Ahmed N, van Geloven N, de Haan RJ, Nederkoorn PJ. Safety and functional outcome of thrombolysis in dissection-related ischemic stroke: a meta-analysis of individual patient data. *Stroke*. 2011 Sep;42(9):2515-20. Epub 2011 Jul 28. Review. **IF: 5.756**